tradingkey.logo
tradingkey.logo

Tempus Announces Strategic Collaboration With Daiichi Sankyo To Advance Ai-Driven Biomarker Discovery And Clinical Differentiation Across An Adc Clinical Program

ReutersMar 25, 2026 12:56 PM

Daiichi Sankyo Co Ltd 4568.T:

  • TEMPUS ANNOUNCES STRATEGIC COLLABORATION WITH DAIICHI SANKYO TO ADVANCE AI-DRIVEN BIOMARKER DISCOVERY AND CLINICAL DIFFERENTIATION ACROSS AN ADC CLINICAL PROGRAM

  • TEMPUS AI : DAIICHI SANKYO WILL LEVERAGE TEMPUS' PROPRIETARY FOUNDATION MODELS AND AI EXPERTISE, INCLUDING PRISM2 MULTIMODAL FOUNDATION MODEL

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI